RE:Pharma faces looming patent cliff - seller's market in bioUber on yahoo has posed a question to independent shareholders, and as I do not own a cell phone and one is required to join yahoo, I shall answer the question here.
The question: I would really love to know exactly what it would take to finally throw in the towel.
My answer: NOTHING.
My reasoning, and I do know I may be wrong.
This is not currently a pretty picture if one is just looking at the share price, and yes it does concern me, but not enough to throw in the towel. It is only by happenstance that we are still here at all. The Bernstein trial kept us in the game, and we regrouped and I dare say not elegantly at times. There does seem to be bots, so there is also that to consider.
I can only look at the science from a lay perspective. The following holds my interest.
The GOBLET trial from all four cohorts, especially the first look at Metastatic Colorectal Cancer.
The treatment of hematological malignancies, specifically the AMBUSH trial, and Dr. Craig Hofmeister and his RRMM plus opdivo trial.
Others will see different reasons for staying.
I believe in surviving.
OUTWIT
OUTPLAY OUTLAST